talactoferrin oral (oral rhLF) - Agennix
BIO CEO & Investor Conference (Agennix) - Feb 14, 2012 - Talactoferrin / Agennix; Anticipated FORTIS-M Phase 3 trial in 3rd line+ NSCLC top line data expected in Q2 2012; Anticipated approval of talactoferrin in 2013 
Anticipated approval • Anticipated top-line data • Non Small Cell Lung Cancer • Oncology
http://www.larvolonline.com/tlg/ccdb/AgennixBIOCEO&InvestorConferenceFeb14'12.pdf
 
Feb 14, 2012
 
Talactoferrin ---- Anticipated FORTIS-M Phase 3 trial in 3rd line+ NSCLC top line data expected in Q2 2012 Anticipated approval of talactoferrin in 2013 ----